ResearchMoz

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

GBI Research
Published Date » 2014-01-16
No. Of Pages » 90
   
 
 GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics (Irritable Bowel Syndrome, Ulcerative Colitis and Crohn’s Disease) in Major Developed Markets’, which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth...
Table of Content

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11

2 Gastrointestinal Therapeutics in Major Developed Markets – Introduction 12
2.1 Irritable Bowel Syndrome 12
2.1.1 Classification 12
2.1.2 Symptoms 12
2.1.3 Etiology 12
2.1.4 Pathophysiology 13
2.1.5 Diagnosis 13
2.1.6 Epidemiology 14
2.1.7 Prognosis 15
2.1.8 Treatment Options 15
2.2 Ulcerative Colitis 16
2.2.1 Classification 16
2.2.2 Symptoms 17
2.2.3 Etiology 17
2.2.4 Pathophysiology 18
2.2.5 Diagnosis 18
2.2.6 Epidemiology 19
2.2.7 Prognosis 19
2.2.8 Treatment Options 20
2.3 Crohn’s Disease 21
2.3.1 Classification 21
2.3.2 Symptoms 22
2.3.3 Etiology 22
2.3.4 Pathophysiology 23
2.3.5 Diagnosis 23
2.3.6 Epidemiology 24
2.3.7 Prognosis 24
2.3.8 Treatment Options 25

3 Gastrointestinal Therapeutics in Major Developed Markets – Marketed Products (Global) 26
3.1 Irritable Bowel Syndrome 26
3.2 Ulcerative Colitis 26
3.3 Crohn’s Disease 26
3.4 Key Marketed Products 27
3.4.1 Amitiza 27
3.4.2 Humira 28
3.4.3 Remicade 29
3.4.4 Simponi 30
3.4.5 Cimzia 31
3.4.6 Tysabri 32

4 Gastrointestinal Therapeutics in Major Developed Markets – Pipeline Analysis 34
4.1 Irritable Bowel Syndrome 34
4.1.1 Overall Pipeline 34
4.1.2 Pipeline Analysis by Molecule Type 36
4.1.3 Pipeline Analysis by Mechanism of Action 37
4.2 Ulcerative Colitis Pipeline 39
4.2.1 Overall Pipeline 39
4.2.2 Pipeline Analysis by Molecule Type 41
4.2.3 Pipeline Analysis by Mechanism of Action 42
4.3 Crohn’s Disease Pipeline 44
4.3.1 Overall Pipeline 44
4.3.2 Pipeline Analysis by Molecule Type 46
4.3.3 Pipeline Analysis by Mechanism of Action 47
4.4 Promising Drug Candidates in the Pipeline 49
4.4.1 GSK-1605786 49
4.4.2 MLN0002 49
4.4.3 EMD-61753 49

5 Gastrointestinal Therapeutics in Major Developed Markets – Market Forecast to 2019 50
5.1 Major Developed Markets 50
5.1.1 Treatment Usage Patterns 50
5.1.2 Annual Cost of Therapy 50
5.1.3 Market Size 50
5.2 US 52
5.2.1 Treatment Usage Patterns 52
5.2.2 Annual Cost of Therapy 52
5.2.3 Market Size 52
5.3 Europe 54
5.3.1 Treatment Usage Patterns 54
5.3.2 Annual Cost of Therapy 54
5.3.3 Market Size 54
5.4 Canada 56
5.4.1 Treatment Usage Patterns 56
5.4.2 Annual Cost of Therapy 56
5.4.3 Market Size 56
5.5 Japan 58
5.5.1 Treatment Usage Patterns 58
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 58
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 60

6 Gastrointestinal Therapeutics in Major Developed Markets – Deals and Strategic Consolidations (Global) 62
6.1 Deals Analysis 62
6.2 Major Co-Development Deals 64
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 65
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 65
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 65
6.3 Major Licensing Deals 66
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 67
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 67
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 67

7 Gastrointestinal Therapeutics in Major Developed Markets – Appendix 68
7.1 All Pipeline Drugs by Phase 68
7.1.1 Discovery 68
7.1.2 Preclinical 68
7.1.3 IND/CTA-filed 69
7.1.4 Phase I 70
7.1.5 Phase II 71
7.1.6 Phase III 73
7.1.7 Pre-Registration 73
7.1.8 Undisclosed 74
7.2 Market Forecasts to 2019 74
7.2.1 Major Developed Markets 74
7.2.2 US 75
7.2.3 Canada 76
7.2.4 UK 77
7.2.5 France 78
7.2.6 Germany 79
7.2.7 Italy 80
7.2.8 Spain 81
7.2.9 Japan 82
7.3 Market Definitions 83
7.4 Abbreviations 83
7.5 Sources 85
7.6 Research Methodology 87
7.6.1 Coverage 87
7.6.2 Secondary Research 87
7.6.3 Primary Research 88
7.6.4 Therapeutic Landscape 88
7.6.5 Geographical Landscape 91
7.6.6 Pipeline Analysis 91
7.7 Expert Panel Validation 91
7.8 Contact Us 91
7.9 Disclaimer 91

List of Tables


Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 12
Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009 16
Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004 16
Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007 18
Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn’s Disease, 2007 19
Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011 21
Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn’s Disease, 2013 21
Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn’s Disease, 2012 22
Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn’s Disease , 2009 25
Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 68
Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 68
Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 69
Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 70
Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 71
Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 73
Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 73
Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 74
Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012–2019 74
Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012–2019 75
Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn’s Disease, Market Forecast, 2012–2019 75
Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012–2019 75
Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012–2019 76
Table 23: Gastrointestinal Therapeutics Market, US, Crohn’s Disease, Market Forecast, 2012–2019 76
Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012–2019 76
Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012–2019 77
Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn’s Disease, Market Forecast, 2012–2019 77
Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012–2019 77
Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012–2019 78
Table 29: Gastrointestinal Therapeutics Market, UK, Crohn’s Disease, Market Forecast, 2012–2019 78
Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012–2019 78
Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012–2019 79
Table 32: Gastrointestinal Therapeutics Market, France, Crohn’s Disease, Market Forecast, 2012–2019 79
Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012–2019 79
Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012–2019 80
Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn’s Disease, Market Forecast, 2012–2019 80
Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012–2019 80
Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012–2019 81
Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn’s Disease, Market Forecast, 2012–2019 81
Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012–2019 81
Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012–2019 82
Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn’s Disease, Market Forecast, 2012–2019 82
Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012–2019 82
Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012–2019 83
Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn’s Disease, Market Forecast, 2012–2019 83

List of Figures


Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007 20
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006–2012 27
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006–2012 28
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006–2012 29
Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009–2012 30
Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008–2012 31
Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006–2012 32
Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013 35
Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 36
Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 38
Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013 40
Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 41
Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 43
Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline, 2013 45
Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Molecule Type, 2013 46
Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Mechanism of Action, 2013 48
Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012–2019 51
Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012–2019 53
Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012–2019 55
Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012–2019 57
Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012–2019 59
Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006–2013 63
Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006–2013 64
Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006–2013 66
Figure 25: GBI Research Market Forecasting Model 90

Upcoming Reports:

Flow Cytometry Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Flow cytometry is a technique used to examine microscopic particles, with the help of fluids, by passing them through an electronic detection apparatus. This technology has a number of applications like molecular biology and immunology but has its major applications in medicine, especially in areas like genetics and chemotherapy. Based on the applications, flow cytometry products are used for monitoring and examining patients. Advancements in the technology and the development of new analysis techniques in combination with medical diagnostics have created favorable conditions...
Biogas Upgrading Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The global biogas upgrading market is expected to reach $338.5 million by the year 2016 at the compounded annual growth rate of 22%. Europe is the largest contributor to the growth of this market and it is expected to hold the market value of $250.5 million in 2016 with CAGR of 22%. Asia Pacific market is projected to reach $83.9 million at a CAGR of 22.8% by the year 2016. Renewable energy is expected to be one of the fastest growing energy sources in the near future. The market for biogas generation is estimated to grow significantly due to its use in number of residential...
Poland: animal fats market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the animal fats market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the animal fats market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Illinois Voicing for Funds to Promote Clean Energy Plants
Mar 26, 2015  
The advocates of renewable energy has been voicing for overhaul of the Illinois’s clean energy law for several years in a row. Refurbishing the law would entail a release of over $100 million that was collected as ratepayer charges that they can invest on payment for new solar and wind projects. However, the proponents could not help the cause and now it seems that the state is...
Michigan To Capitalize on Clean and Local Energy
Mar 26, 2015  
For years now Americans have been campaigning to promote “eat locally and shop locally” culture. Inspired from the drive, Michiganders have got on board the plan to locally harness the energy to power their lives.  It will be very interesting to see how Gov. Rick Snyder’s vision of “no-regret energy future”, which has its key focus on curbing the...
Noble Energy Pulls Out from Ruth C License Exploration
Mar 26, 2015  
Citing issues related to “regulatory uncertainty”, in the energy and gas sector of Israel, the Houston-based company named Noble Energy forwent with its permit for operation in the Ruth C exploration license, as reported by Tel Aviv Stock Exchange on Thursday.  The Ruth C license zone is located off the Haifa coast, to the east of the larger Tamar basin. Energy reserve...
Leaders Go Back to School to Motive Students to Join the Construction Industry
Mar 26, 2015  
The housing sector is facing a major shortage in UK as the region suffers from lack of skilled construction workers. Amidst this crisis, two of the industry leaders are touring schools to encourage students to be a part of the industry which so desperately needs them. According to the Construction Industry Training Board, UK needs a workforce of 180,000 or more with adequate skill sets...
Israel Freezes Construction of 1,500 New Housing Units
Mar 26, 2015  
Israel has scrapped the plan to build 1,500 new housing units in East Jerusalem. The decision comes despite Prime Minister Benjamin Netanyahu's announcement to continue construction regardless of international pressure. East Jerusalem is the neighboring region of Har Homa, a little beyond the Green Line.  From the looks of it, the construction plan in Har Homa seems to have been...